William K. Oh, MD

William K. Oh, MD, chief, Division of Hematology and Medical Oncology,&nbsp;and professor of medicine and urology, Mount Sinai Hospital, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Patients with mHSPC were randomized to receive testosterone suppression plus either enzalutamide (Xtandi) or a standard anti-androgen therapy. There was a significant survival benefit in favor of the enzalutamide arm, Oh says, but this was not surprising based on data from STAMPEDE and LATITUDE, which both compared similar agents.

What was unique about the ENZAMET trial was that 45% of patients were allowed to receive chemotherapy, per the physician&rsquo;s choice. There was no prespecified randomization, which helped to answer the remaining question from prior trials of whether chemotherapy or androgen receptortargeted therapy is better in this setting. Although these data do not definitively answer this question, the trial did show all benefit from enzalutamide was seen in patients that did not also receive chemotherapy. Oh concludes that there may have been cross activity between 6 cycles of docetaxel chemotherapy and the benefit of enzalutamide.

Videos

William K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.

Evaluating Significance of ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and&nbsp;urology, Mount Sinai School of Medicine, discusses the use of abiraterone (Zytiga) and docetaxel (Taxotere) in patients with&nbsp;metastatic prostate cancer.

The management of metastatic hormone-sensitive prostate cancer has been one of the biggest developments in the treatment of advanced prostate cancer in the past several years, Oh says. The results of a large randomized trial, CHAARTED, which compared androgen-deprivation therapy (ADT) versus ADT plus 6 cycles of docetaxel in newly-diagnosed patients with hormone-sensitive disease were presented in 2014. It was a positive study, favoring the use of chemotherapy. The STAMPEDE study then confirmed those findings.

In 2017, the results of the LATITUDE study were presented. This large, randomized study compared ADT plus or minus abiraterone and showed a comparable benefit of up to 2 to 3 years of abieratone plus prednisone in the treatment of metastatic hormone-sensitive prostate cancer.

In total, there are now 4 clinical trials that have shown either docetaxel or abiraterone significantly improves survival compared to ADT alone. Now, the remaining question is which of these agents is better, Oh says.

this treatment combination for prostate cancer

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of&nbsp;medicine and&nbsp;urology, Mount Sinai School of Medicine, discusses the use of abiraterone and docetaxel in patients with&nbsp;metastatic castration-resistant prostate cancer.&nbsp;

Dr. Oh Discusses the Use of Abiraterone and Docetaxel in Prostate Cancer

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.

Cabazitaxel was approved several years ago for patients with prostate cancer who progress on docetaxel.

Chemotherapy has a clear benefit in treating prostate cancer.

The CHAARTED study will likely change the way cabazitaxel is used in practice.

The Utility of Cabazitaxel

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses immunotherapies for the treatment of patients with prostate cancer.

Articles

William K. Oh, MD, discusses immunotherapies for the treatment of patients with prostate cancer.


Immunotherapies for Prostate Cancer

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the process of validating a whole-blood prognostic signature in metastatic castration-resistant prostate cancer (mCRPC).

A previously identified six-gene signature, (

) was likely derived from immune cells, not cancer

Since this signature was found to be prognostic, this could indicate that the body&rsquo;s reaction to cancer is as important as the cancer itself

The primary question now is whether or not this data can be easily quantified by measuring a biomarker in the blood reproducibly in a commercially available test

Work is ongoing with diagnostic companies to commercialize the six-gene prognostic signature

Validating Gene Signatures in mCRPC

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Satraplatin is a next-generation chemotherapy drug that will not move forward in development

It is known that there is a subset of patients with advanced CRPC that respond to platinum chemotherapy

Blood- and tissue-based biomarkers are in development to predict the subset of patients that will respond

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.